Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00898690|
Recruitment Status : Unknown
Verified May 2006 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : May 12, 2009
Last Update Posted : December 18, 2013
RATIONALE: DNA analysis of tumor tissue may help doctors predict how patients who receive paclitaxel will respond to treatment.
PURPOSE: This laboratory study is evaluating gene expression in predicting response to paclitaxel in patients with breast cancer.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Genetic: cytogenetic analysis Genetic: gene expression analysis Genetic: microarray analysis Genetic: mutation analysis Genetic: reverse transcriptase-polymerase chain reaction Other: immunohistochemistry staining method|
- Determine whether loss of function of the FEZ1/LZTS1 gene is a predictor of response in patients with breast cancer treated with paclitaxel.
OUTLINE: This is a single-blind study.
Tumor tissue is analyzed for FEZ1/LZTS1 gene expression by immunohistochemistry using an antibody for the gene. Tumor expression of the gene is characterized by immunohistochemistry and scored by intensity of staining, percent of cell staining, and staining index. Tumor tissue is also analyzed for FEZ1/LZTS1 gene disruption by reverse transcriptase-polymerase chain reaction and direct sequencing.
PROJECTED ACCRUAL: Approximately 120 patients will be accrued for this study.
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Official Title:||Determination Of FEZ1/LZTS1 Expression As A Predictor Of Response To Taxol|
|Study Start Date :||March 2003|
- Evaluation of the association between tumor expression of FEZ1/LZTS1 gene and response to paclitaxel
- Utility of FEZ1/LZTS1 gene expression in predicting the full 4-level response pattern (complete response, partial response, stable disease, progressive disease)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898690
|Principal Investigator:||Carlo M. Croce, MD||Sidney Kimmel Cancer Center at Thomas Jefferson University|